title: Medical ozone and radiotherapy in a peritoneal, Erlich-ascites, tumor-cell model.
abstract: BACKGROUND
  Medical ozone therapy is used for treatment of inflammation in alternative and complementary medicine. It has been reported that the beneficial effects of radiotherapy increased with the addition of medical ozone therapy.
  
  
  OBJECTIVE
  This study intended to investigate the antitumor and antiedema effects of ozone therapy when applied in different concentrations in mice with peritoneal carcinomatosis (PC) and to evaluate the contribution of medical ozone therapy to the outcomes for radiotherapy in vivo.
  
  
  METHODS
  Ehrlich ascites carcinoma (EAC) cells were inoculated intraperitoneally (IP) to develop peritoneal carcinomatosis in 60 adult male Swiss albino mice. The animals were divided into 5 groups. Groups 1 and 2 were treated IP for a period of 10 d with daily medical ozone therapy. Group 3 received radiotherapy into the abdomen for 5 d. Groups 4 and 5 were treated with medical ozone therapy for 10 d and radiotherapy for 5 d. Groups 1 and 4 received a 20 mg/L concentration of ozone and groups 2 and 5 received a 40 mg/L concentration. A sixth group acted as controls, and serum physiologic was given to them IP.
  
  
  METHODS
  Changes in body weight and abdominal circumference were measured daily for each mouse. Survival rates of the groups of mice were also determined. The results were compared between groups and were statistically analyzed.
  
  
  RESULTS
  Changes in body weights and abdominal circumferences in the different groups were statistically different. The longest survival rates were found for groups 3 and 5, and survival rates for the 5 experimental groups were significantly higher than for the control group.
  
  
  CONCLUSIONS
  Medical ozone therapy or radiotherapy was found to be effective when administered alone or concurrently to mice with PC, suggesting that medical ozone therapy might serve as a method of obtaining antiedema and antitumor effects, providing a longer survival time.
authors.forename: Huriye Şenay
authors.initials: HŞ
authors.lastname: Kızıltan
authors.forename: Ayşe Güneş
authors.initials: AG
authors.lastname: Bayir
authors.forename: Gul
authors.initials: G
authors.lastname: Yucesan
authors.forename: Ali Hikmet
authors.initials: AH
authors.lastname: Eris
authors.forename: Kadir
authors.initials: K
authors.lastname: İdin
authors.forename: Cumali
authors.initials: C
authors.lastname: Karatoprak
authors.forename: Teoman
authors.initials: T
authors.lastname: Aydin
authors.forename: Adem
authors.initials: A
authors.lastname: Akcakaya
authors.forename: Alpaslan
authors.initials: A
authors.lastname: Mayadagli
mesh_terms: D000818:Animals; D001201:Ascites / Q000188:drug therapy* / Q000532:radiotherapy*; D001835:Body Weight; D000529:Complementary Therapies / Q000379:methods*; D008297:Male; D051379:Mice; D010126:Ozone / Q000627:therapeutic use*; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D016019:Survival Analysis
chemical_list: D010126:Ozone